What is the recommended management plan for diabetes mellitus?

Diabetes Management

For adults with type 2 diabetes, initiate metformin as first-line therapy combined with comprehensive lifestyle modification, and prioritize adding GLP-1 receptor agonists or SGLT2 inhibitors based on the presence of cardiovascular disease, heart failure, or chronic kidney disease—independent of glucose control. 1

Initial Pharmacologic Approach

Metformin as Foundation Therapy

Metformin remains the preferred initial agent for most newly diagnosed adults with type 2 diabetes 1. Continue metformin indefinitely unless contraindicated or not tolerated. Key considerations:

• Low hypoglycemia risk, weight neutral, durable glucose-lowering effects
• Contraindications: Do not use with eGFR <30 mL/min/1.73 m² or initiate with eGFR <45 mL/min/1.73 m²
• Dose adjustment: Reduce total daily dose when eGFR 30-45 mL/min/1.73 m²
• Monitor vitamin B12 levels periodically with long-term use 1
• Common GI side effects (nausea, diarrhea) can be minimized by starting low and titrating slowly

Comorbidity-Driven Drug Selection (Priority Over Glucose Levels)

This is critical: If the patient has established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, prescribe a GLP-1 receptor agonist or SGLT2 inhibitor with proven efficacy for that specific condition—regardless of current A1C or glucose control 1. This represents a fundamental shift from glucose-centric to comorbidity-centric management.

Glycemic Severity-Based Treatment Algorithms

A1C <7.5%

Start metformin monotherapy (or acceptable alternatives if metformin contraindicated: GLP-1 RA, SGLT2i, DPP-4 inhibitor, or alpha-glucosidase inhibitor) 2

A1C 7.5-9.0%

Initiate dual therapy immediately:

• Metformin PLUS a second agent with low hypoglycemia risk
• Preferred second agents: GLP-1 receptor agonist, SGLT2 inhibitor, or DPP-4 inhibitor 1
• These agents are weight-neutral or promote weight loss and minimize hypoglycemia risk 1

A1C >9.0% Without Symptoms

Start dual or triple combination therapy:

• Metformin plus GLP-1 RA and/or SGLT2i
• Consider adding basal insulin if A1C ≥1.5% above target 1

A1C >9.0% With Symptomatic Hyperglycemia

Insulin is mandatory when patients present with:

• Catabolic features (unintentional weight loss)
• Blood glucose ≥300 mg/dL (16.7 mmol/L)
• A1C >10%
• Ketosis

Start basal insulin (with or without prandial insulin) plus metformin 2, 1

Insulin Therapy Specifics

When to Initiate Insulin

Prescribe insulin when noninsulin therapy fails to achieve glycemic targets OR when symptomatic hyperglycemia is present 1

Preferred Insulin Regimens

• Long-acting basal insulin analogs (glargine U100/U300, degludec U100/U200, or detemir) are preferred over NPH insulin due to lower hypoglycemia risk 1, 3
• Starting dose: 10 units or 0.1-0.2 units/kg body weight 4
• Continue metformin when adding basal insulin

Intensification Strategy

When basal insulin alone is insufficient:

1. First choice: Add GLP-1 receptor agonist (preferred over prandial insulin) 1
2. Alternative: Switch to fixed-ratio combination (insulin glargine + lixisenatide OR insulin degludec + liraglutide) 1
3. If further intensification needed: Add rapid-acting prandial insulin (lispro, aspart, or glulisine) before meals 4

Type 1 Diabetes Management

Treat with multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII) using insulin analogs 3. Key components:

• Basal-bolus regimen: Long-acting basal insulin plus rapid-acting prandial insulin
• Insulin analogs preferred over human insulin to minimize hypoglycemia 3
• Automated insulin delivery systems should be offered to all adults with type 1 diabetes 3
• Continuous glucose monitoring (CGM) recommended early for improved outcomes and reduced hypoglycemia 3
• Carbohydrate counting education is essential for matching mealtime insulin doses 3

Lifestyle Management Foundation

All pharmacologic therapy must be combined with:

Medical Nutrition Therapy

• No single ideal macronutrient distribution—individualize based on metabolic goals 5
• Emphasize carbohydrates from vegetables, fruits, legumes, whole grains, and high-fiber foods with lower glycemic load 5
• Avoid sugar-sweetened beverages to control weight and reduce cardiovascular risk 5
• Mediterranean-style diet rich in monounsaturated/polyunsaturated fats improves glucose metabolism and lowers CVD risk 5
• Sodium restriction: <2,300 mg/day 5

Weight Management

Weight loss ≥5% benefits overweight/obese adults with type 2 diabetes through calorie reduction and lifestyle modification 5

Physical Activity

Both aerobic and resistance training improve insulin sensitivity and glucose control 6

Critical Pitfalls to Avoid

1. Don't delay insulin when clinically indicated—timely initiation prevents metabolic decompensation 4
2. Avoid sulfonylureas as preferred agents—they cause hypoglycemia and weight gain, undermining benefits of other medications 1
3. Don't ignore comorbidities—cardiovascular and renal protection takes precedence over glucose lowering alone 1
4. Never use metformin with eGFR <30—risk of lactic acidosis 1
5. Don't continue oral agents unnecessarily when complex insulin regimens are used—discontinue sulfonylureas, DPP-4 inhibitors, and GLP-1 RAs when multiple daily insulin injections are started 4

Monitoring and Adjustment

• Reassess quarterly or more frequently: medication adherence, safety, glycemic control 1
• Glycemic targets include: A1C, blood glucose monitoring, and for CGM users—time in range, time below range, and glycemic variability 1
• Titrate insulin doses based on self-monitoring of blood glucose or CGM data 4
• Adjust treatment every 3 months when targets are not achieved 2